Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05945602 · ClinicalTrials.gov registry record
Neurophysiologic Biomarkers for Cognitive Rehabilitation
A clinical trial of Schizophrenia Spectrum Disorders, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT05945602: Recruiting study of Schizophrenia Spectrum Disorders, sponsored by VA Office of Research and Development.
NCT05945602 is a study of Schizophrenia Spectrum Disorders that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05945602, a study of Schizophrenia Spectrum Disorders, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance the clinical impact of cognitive remediation and other rehabilitative interventions for Veterans living with chronic psychosis, this study will develop novel brain-based tools to help identify those Veterans who are most likely to benefit from pro-cognitive therapies. These studies may advance predictive algorithms that improve functional outcomes and life quality in Veterans with schizophrenia.
Primary Outcome
Estimates of aperiodic activity will be calculated from electroencephalography recordings collected at baseline (Day 1) and approximately 7 days later.
Conditions Studied
Interventions
- OTHER Neurophysiologic Biomarker Assessments
Study Locations (1)
California
- VA San Diego Healthcare System, San Diego, CA - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2028-09-30 |
What NCT05945602 shows while recruiting
NCT05945602 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 1 condition, with Schizophrenia Spectrum Disorders appearing as the primary indexed condition, and to 1 intervention - of which Neurophysiologic Biomarker Assessments is the first listed.
NCT05945602 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05945602 about?
NCT05945602 is a clinical study titled "Neurophysiologic Biomarkers for Cognitive Rehabilitation". Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizop...
What is the current status of trial NCT05945602?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2023-10-01. Estimated completion is 2028-09-30.
What conditions does trial NCT05945602 study?
This clinical trial studies the following conditions: Schizophrenia Spectrum Disorders.
What interventions are being tested in trial NCT05945602?
The interventions under investigation include: Neurophysiologic Biomarker Assessments (OTHER).
Who is sponsoring clinical trial NCT05945602?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05945602 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia Spectrum Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI